Belite Bio, Inc. (NASDAQ:BLTE) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Â Company Participants Tom Lin - Chairman and Chief Executive Officer Basma Radwan - Leerink Partners Yi Chen - HC Wainwright Hello and thank you for joining us to discuss BeliteÂ's Third Quarter 2023 Financial Results. Joining the call is Dr. Tom Lin, Chairman and CEO, Dr. Nathan Mata, Chief Scientific Officer, and Hao-Wan Zhang, Chief Financial Officer of BeLite Bio. Before we begin, let me point out that we will ...

| --- | --- | --- | |-------|-------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | | | | | | | Early Intervention with | | | | Mission for Vision Nasdaq: BLTE Media and Investor Relations Contact: Jennifer Wu / ir@belitebio.com an Oral Treatment for Macular Degeneration | | Any statements in this presentation about Belite Bio's future expectations, plans and prospects constitute forward-looking state ...

Conference Call Participants Basma Radwan - Leerink Partners Operator Good morning, and welcome to the Belite Bio Q2 2023 Financial Results Conference Call. At this time, all attendees are in a listen-only mode. A question-and-answer session will follow the formal presentations. [Operator Instructions] As a reminder, this call is being recorded and a replay will be made available on the Belite Bio website following the conclusion of the event. With that, IÂ'd like to turn the call over to your host Tom Lin, ...

Forward-Looking Statements and Legal Disclaimer Any statements in this presentation about Belite Bio's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements about the strategy, operations and future expectations and plans and prospects for the Company, and any other statements containing the words "expect," "intend", "plan," "predict," ...

Belite Bio, Inc (NASDAQ:BLTE) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Operator Thank you, Tara. Thank you, everyone, for joining our financial results for first quarter 2023. Joining me today is our CSO, Nathan Mata, who will be updating our recent clinical trial progress; and our CFO, Hao-Yuan, who will be updating our Q1 financial results. And now I would like to pass it on to our CSO to give an update on our clinical trials. Nathan? In fact, we've had interim analyses that's periodically ...

Belite Bio, Inc (NASDAQ:BLTE) Q4 2022 Earnings Conference Call April 3, 2023 4:30 PM ET Company Participants Tom Lin - Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Lachlan Hanbury-Brown - William Blair Yi Chen - H.C. Wainwright Bruce Jackson - The Benchmark Company Yuan Zhi - B. Riley Securities Operator Good afternoon and welcome to the Belite Bio 2022 Full Year Financial Results Confer ...

17 The incidence and prevalence for target patient populations of our product candidates are based on estimates and third-party sources. The market opportunities for our product candidates, if approved, may be smaller than we anticipate. The illegal importation of competing products from countries where government price controls or other market dynamics result in lower prices may adversely affect the demand for our future approved product candidates and, in turn, may adversely affect our sales and profitabi ...

Belite Bio, Inc (NASDAQ:BLTE) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Tom Lin – Chief Executive Officer Nathan Mata – Chief Scientific Officer Hao-Yuan Chuang – Chief Financial Officer Conference Call Participants Bruce Jackson – The Benchmark Company Unidentified Company Representative [Call Starts Abruptly] First Half 2022 Financial Results Conference Call. After todayÂ's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please no ...